Contact Pathway in Surgical and Transcatheter Aortic Valve Replacement

Background: Aortic valve replacement is the gold standard treatment for severe symptomatic aortic stenosis, but thrombosis of bioprosthetic valves (PVT) remains a concern.

Objective: To analyze the factors involved in the contact pathway during aortic valve replacement and to assess their impact on the development of thromboembolic complications.

Methods: The study was conducted in 232 consecutive patients who underwent: transcatheter aortic valve replacement (TAVR, = 155), and surgical valve replacement (SAVR, = 77) (MUVITAVI project). Demographic and clinical data, outcomes including a combined end point (CEP) of thrombotic events, and imaging controls were recruited. Samples were collected 24 h before and 48 h after valve replacement. FXII, FXI and (pre)kallikrein were evaluated by Western Blot and specific ELISA with nanobodies.

Results: The CEP of thrombotic events was reached by 19 patients: 13 patients presented systemic embolic events and 6 patients subclinical PVT. Valve replacement did not cause FXII activation or generation of kallikrein. There was a significant reduction of FXI levels associated with the procedure, which was statistically more pronounced in SAVR than in TAVR. Cases with reductions of FXI below 80% of basal values had a lower incidence of embolic events during the procedure than patients in whom FXI increased above 150%: 2.7 vs. 16.7%; : 0.04.

Conclusion: TAVR or SAVR did not significantly activate the contact pathway. A significant reduction of FXI, was observed, particularly in SAVR, associated with lower incidence of thrombotic events. These results encourage evaluating the usefulness and safety of FXI-directed antithrombotic treatments in these patients.

Citing Articles

Patient - prosthesis mismatch and its influence on immediate postoperative Von Willebrand factor levels in aortic valve replacement surgery.

Grigorescu A, Anghel A, Matichescu A, Feier H Med Pharm Rep. 2025; 98(1):21-28.

PMID: 39949912 PMC: 11817581. DOI: 10.15386/mpr-2811.

Von Willebrand Factor Dynamics in Patients with Aortic Stenosis Undergoing Surgical and Transcatheter Valve Replacement.

Grigorescu A, Anghel A, Koch C, Horhat F, Savescu D, Feier H Life (Basel). 2024; 14(8).

PMID: 39202676 PMC: 11355308. DOI: 10.3390/life14080934.

References

Pauer H, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I . Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost. 2004; 92(3):503-8. DOI: 10.1160/TH04-04-0250. View

Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N . A common genetic polymorphism (46 C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood. 1998; 91(6):2010-4. View

Lopez-Galvez R, de la Morena-Barrio M, Lopez-Lera A, Pathak M, Minano A, Serrano M . Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. Orphanet J Rare Dis. 2020; 15(1):280. PMC: 7547467. DOI: 10.1186/s13023-020-01564-9. View

Renne T, Stavrou E . Roles of Factor XII in Innate Immunity. Front Immunol. 2019; 10:2011. PMC: 6713930. DOI: 10.3389/fimmu.2019.02011. View

Corvillo F, de la Morena-Barrio M, Marcos-Bravo C, Lopez-Trascasa M, Vicente V, Emsley J . The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant. Front Genet. 2020; 11:1033. PMC: 7549737. DOI: 10.3389/fgene.2020.01033. View

Renne T, Pozgajova M, Gruner S, Schuh K, Pauer H, Burfeind P . Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005; 202(2):271-81. PMC: 2213000. DOI: 10.1084/jem.20050664. View

Silasi R, Keshari R, Regmi G, Lupu C, Georgescu C, Simmons J . Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus. Blood. 2021; 138(2):178-189. PMC: 8288658. DOI: 10.1182/blood.2020009345. View

Yau J, Liao P, Fredenburgh J, Stafford A, Revenko A, Monia B . Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014; 123(13):2102-7. DOI: 10.1182/blood-2013-12-540872. View

Long A, Kenne E, Jung R, Fuchs T, Renne T . Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2015; 14(3):427-37. DOI: 10.1111/jth.13235. View

10.

Schwarz J, Cooper D, Schuelke M, Seelow D . MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014; 11(4):361-2. DOI: 10.1038/nmeth.2890. View

11.

Brown J, OBrien S, Wu C, Sikora J, Griffith B, Gammie J . Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg. 2009; 137(1):82-90. DOI: 10.1016/j.jtcvs.2008.08.015. View

12.

Salomon O, Steinberg D, Zucker M, Varon D, Zivelin A, Seligsohn U . Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2010; 105(2):269-73. DOI: 10.1160/TH10-05-0307. View

13.

Wallisch M, Lorentz C, Lakshmanan H, Johnson J, Carris M, Puy C . Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates. Res Pract Thromb Haemost. 2020; 4(2):205-216. PMC: 7040549. DOI: 10.1002/rth2.12309. View

14.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

15.

de Maat S, van Dooremalen S, de Groot P, Maas C . A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost. 2013; 110(3):458-68. DOI: 10.1160/TH12-11-0792. View

16.

Bravo-Perez C, Rodenas T, Esteban J, de la Morena-Barrio M, Salloum-Asfar S, de la Morena-Barrio B . Gynaecological and obstetrical bleeding in Caucasian women with congenital factor XI deficiency: Results from a twenty-year, retrospective, observational study. Med Clin (Barc). 2019; 153(10):373-379. DOI: 10.1016/j.medcli.2019.01.029. View

17.

Makkar R, Blanke P, Leipsic J, Thourani V, Chakravarty T, Brown D . Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy. J Am Coll Cardiol. 2020; 75(24):3003-3015. DOI: 10.1016/j.jacc.2020.04.043. View

18.

Jimenez Diaz V, Lozano I, Tello Montoliu A, Baz Alonso J, Iniguez Romo A . Is There a Link Between Stroke, Anticoagulation, and Platelet Reactivity?: The Multifactorial Stroke Mechanism Following TAVR. JACC Cardiovasc Interv. 2019; 12(24):2560-2561. DOI: 10.1016/j.jcin.2019.10.004. View

19.

Srivastava P, Gailani D . The rebirth of the contact pathway: a new therapeutic target. Curr Opin Hematol. 2020; 27(5):311-319. PMC: 7596882. DOI: 10.1097/MOH.0000000000000603. View

20.

Simao F, Feener E . The Effects of the Contact Activation System on Hemorrhage. Front Med (Lausanne). 2017; 4:121. PMC: 5534673. DOI: 10.3389/fmed.2017.00121. View